ICMR-VRDL Study: All Four Dengue Serotypes Co-Circulate in 8 States, 7% Patients Have Concurrent Infections

ICMR Study: 61% Gram-Negative Infections Carbapenem-Resistant; Mortality 39-51%

A large ICMR study across 20 Indian hospitals (2022-2025) reveals that carbapenem-resistant Gram-negative infections cause significantly higher mortality (39-51% in bloodstream infections) and cost 1.1-2 times more to treat. The study stresses that antimicrobial resistance is a complex interplay of healthcare transmission, antibiotic pressure, and diagnostic gaps, not just antibiotic overuse.

Candida auris Shows 90% Azole Resistance; Study Reveals Gene Duplication & Eagle Effect Challenging Antifungals

Fungal infections are rising due to global warming, with Candida auris emerging as a multidrug-resistant threat (30-40% mortality). New research from JNCASB and collaborators reveals that C. auris uses gene duplication (Erg11) and mutations (Fks1) to resist antifungals, and also exhibits the 'Eagle effect' where high drug doses paradoxically trigger compensatory chitin production, making the pathogen survive. This signals the end of the chemical arms race approach and calls for combination therapies and revised susceptibility testing limits.

Proposed Patient Data Collective (PDC) Model for Rare Diseases in India Inspired by Amul Cooperative

A new proposal suggests creating a Patient Data Collective (PDC) for rare diseases in India, modeled on the Amul dairy cooperative. This collective would pool patient data to accelerate drug discovery and clinical trials, addressing the challenge of small patient populations for rare diseases.

Cabinet Approves Rs 23,731 Cr GOBARdhan Scheme; Rajya Sabha Clears Rs 54,067 Cr Appropriation Bill

The UPSC Key article covers multiple critical topics: the Rajya Sabha cleared the Appropriation Bill for Rs 54,067 Cr excess expenditure, the Cabinet approved the Rs 23,731 Cr GOBARdhan scheme to boost CBG production, and new high-resolution images of the Sun's surface were captured. Also includes data on road safety Good Samaritans, school consolidation, and ethanol policy.

Merck-Moderna mRNA Drug Intismeran Autogene Cuts Melanoma Recurrence in Phase 3 Trial with 1,137 Patients

For the first time, an mRNA-based personalized cancer vaccine (intismeran autogene) developed by Merck and Moderna has proven effective in reducing melanoma recurrence in a large late-stage trial with 1,137 patients. This marks a breakthrough in cancer immunotherapy, demonstrating that mRNA technology, previously successful against COVID-19, can be adapted to fight cancer.

VP Launches India Valve Registry for Heart Valve Disease Research; TN Reports 2,590 Valve Replacements in 20 Months

The Vice-President launched the India Valve Registry, a first-of-its-kind clinician-led platform to collect real-world data on valvular heart disease and interventions in India. The registry will generate India-specific evidence to improve patient care, while Tamil Nadu's CMCHIS data reveals 2,590 valve replacements in 20 months, highlighting the burden of rheumatic heart disease and the success of state-led healthcare.

CDSCO Approves Qdenga Dengue Vaccine for Ages 4-60; Dr. Reddy's to Distribute in Private Market by 2027

India's first approved dengue vaccine, Qdenga (TAK-003), developed by Takeda, received CDSCO marketing authorisation in July 2026 for ages 4-60. Dr. Reddy's will promote and distribute it in the private market from the first half of 2027, while Takeda retains public market rights. This marks a critical step in addressing India's 11-fold rise in dengue cases over two decades.

CDSCO Approves Qdenga: India's First Dengue Vaccine to be Distributed by Dr Reddy's from 2027

India’s first approved dengue vaccine Qdenga will enter the private market in 2027 via Dr Reddy’s, after CDSCO approval in July 2026. The vaccine is effective against all four serotypes, requires no pre-vaccination screening, and shows 61.2% efficacy against dengue and 84.1% against hospitalization. This is a landmark step in India's fight against dengue.